Scientists at University of Hong Kong discuss research in oral tongue cancer
2009 JUL 20 - (NewsRx.com) -- "There are controversies on the benefits of elective neck dissection (END) for oral tongue carcinoma. This is a prospective randomized study of elective selective I, II, III neck dissection versus observation for NO neck of stage I to II oral tongue carcinoma, There were 35 patients on the observation arm and 36 patients on the END arm," scientists in Hong Kong, People's Republic of China report. "The main outcome assessment parameters are node-related mortality and disease-specific survival rate. There were II patients in the observed arm and 2 patients in the END arm who developed nodal recurrence alone without associated local or distant recurrence. All 13 patients were salvaged, and no patient died of nodal recurrence. The 5-year disease-specific survival rate was 87% for the observation arm and was 89% for the END arm; the 2% difference was not significant," wrote A.P.W. Yuen and colleagues, University of Hong Kong. The researchers concluded: "Observation may be an acceptable alternative to END if strict adherence to a cancer surveillance protocol is followed." Yuen and colleagues published their study in Head and Neck - Journal for the Sciences and Specialties of the Head and Neck (PROSPECTIVE RANDOMIZED STUDY OF SELECTIVE NECK DISSECTION VERSUS OBSERVATION FOR NO NECK OF EARLY TONGUE CARCINOMA. Head and Neck - Journal for the Sciences and Specialties of the Head and Neck, 2009;31(6):765-772). For additional information, contact A.P.W. Yuen, University of Hong Kong, Queen Mary Hospital, Dept. of Surgery, Hong Kong, Hong Kong, People's Republic of China. The publisher's contact information for the Head and Neck - Journal for the Sciences and Specialties of the Head and Neck is: John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA. Keywords: People's Republic of China, Hong Kong, Oncology, Oral Tongue Cancer, Oral Tongue Carcinoma, Otorhinolaryngology, University of Hong Kong. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|